Management of Heavy Menstrual Bleeding (Menorrhagia) and Hemoglobin Level through Panchakarma Therapy (Basti Karma) and Ayurvedic Medicine

Comparative Efficacy of Chandanadi Basti along with Pradarantaka Lauha and Pradarantaka Lauha Alone on Hemoglobin level in Patients with Raktapradara (w.s.r Menorrhagia) - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/080050

Enrollment

Registered

2025-02-07

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N92- Excessive, frequent and irregularmenstruation

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Heavy menstrual flow greater than 80ml/cycle 2. Hemoglobin level 7.0-10.9gm/dl 3. Patient willing to provide written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients who are contraindicated for Niruha basti and Anuvasana basti, will not be included in Group A. 2. Pregnant women and lactating mothers. 3. Known cases of aplastic anemia, sickle cell anemia, thalassemia, autoimmune hemolytic anemia, chronic blood loss anemia like gastrointestinal bleeding or any infection or any documented history of blood disorders. 4. Patients with co-morbid conditions such as Hypertension (systolic greater than 150 mm Hg and diastolic greater than 100 mm Hg despite antihypertensive) and Diabetes Mellitus (having HbA1c greater than 7.0% despite anti-diabetic medications). 5. Patients planning to undergo or already had any gynecological surgery. 6. Patients suffering from major illnesses such as malignancy, Ascites, Intestinal perforation, Intestinal obstruction etc. 7. Patients with severe impairment in LFT and KFT. 8. Patients on antiretroviral, anti-tuberculosis, anticoagulants, anticonvulsants, psychotropic medications, cardiovascular agents, or immunosuppressants. 9. Excluding patients who have uterine fibroids that are specifically responsible for causing bleeding per vagina. 10. Causes of bleeding per vagina such as polyps, adenomyosis, (malignancy, and hyperplasia, as ruled out through a per-speculum examination, USG pelvis, or other symptoms)

Design outcomes

Primary

Measure	Time frame
The primary outcome will be the change in hemoglobin level from baseline in patients with Raktapradara (w.s.r Menorrhagia) ( for both the group A and B)Timepoint: The primary outcome will be the change in hemoglobin level from baseline in patients with Raktapradara (w.s.r Menorrhagia) ( for both the group A and B) at 30, 60 and 90th days	—

Secondary

Measure	Time frame
The secondary outcome will be the change in the grading of clinical features of Raktapradara (w.s.r Menorrhagia) & Assessment of menstrual blood loss from the baseline.Timepoint: Secondary outcomes will be measured by through grading system of clinical features of Raktapradara (w.s.r Menorrhagia) & Menstrual blood loss will be assessed by using the PBAC (Pictorial Blood Loss Assessment Chart) at 90th day	—

Measure

Time frame

The secondary outcome will be the change in the grading of clinical features of Raktapradara (w.s.r Menorrhagia) & Assessment of menstrual blood loss from the baseline.Timepoint: Secondary outcomes will be measured by through grading system of clinical features of Raktapradara (w.s.r Menorrhagia) & Menstrual blood loss will be assessed by using the PBAC (Pictorial Blood Loss Assessment Chart) at 90th day

—

Countries

India

Contacts

Public ContactAyushi Gupta

Ayurvedic and Unani Tibbia College And Hospital

nitjin2005@gmail.com9811765501

Outcome results